HormonesTestosterone Prescribing Rises Among Women as Recorded Monitoring Remains Low
Testosterone prescribing among women is increasing, but this study raises questions about treatment selection and monitoring. Researchers examined electronic health records for 10,185 adult women newly prescribed testosterone between 2016 and 2024. Only 17% had a recorded diagnosis of hypoactive sexual desire disorder, which the authors identify as the only evidence-based indication in postmenopausal women. New prescribing increased by an estimated 22% annually from 2022 to 2024. Blood testing was recorded for 16% before treatment and 10% during follow-up; among those tested afterward, 38% had testosterone levels above 70 ng/dL. Most received one prescription, while some continued beyond two years, where safety evidence is limited. These findings support reviewing treatment goals and monitoring, but incomplete records cannot establish inappropriate care or treatment-related harm. This summary uses the abstract only.